Clinical Study | Office of Clinical Research

Everest: Everolimus For Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Posted Date: May 15, 2019

Investigator: Shuchi Gulati
Type of Study: Drug

This study is to find out if everolimus after surgery for kidney cancer will increase the time without cancer returning. Studies suggest one way kidney cancer grows is through chemical signaling through a protein called ?mTOR?. Everolimus is a drug that stops signaling through mTOR and may therefore

Criteria:

Eligible Patients Must Have Kidney Cancer That Has Been Removed By Surgery

Keywords:

Genitourinary Cancer, Kidney Cancer, Renal Cancer, S0931

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List